Bristol Myers Squibb Presents First Phase 3 Data on KarXT
Bristol Myers Squibb presented first clinical data from two Phase 3 studies in the ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease.
Bristol Myers Squibb presented first clinical data from two Phase 3 studies in the ADEPT program evaluating KarXT for psychosis associated with Alzheimer’s disease.